Canagliflozin/teneligliptin

Drug Profile

Canagliflozin/teneligliptin

Alternative Names: CANALIA; MT-2412; TA-7284/MP-513; Teneligliptin/canagliflozin

Latest Information Update: 04 Jul 2017

Price : $50

At a glance

  • Originator Mitsubishi Tanabe Pharma Corporation
  • Class Antihyperglycaemics; Glucosides; Ketones; Piperazines; Pyrazoles; Small molecules; Thiazolidines; Thiophenes
  • Mechanism of Action CD26 antigen inhibitors; Sodium-glucose transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Registered Type 2 diabetes mellitus

Most Recent Events

  • 03 Jul 2017 Registered for Type-2 diabetes mellitus (Treatment-experienced) in Japan (PO)
  • 29 Mar 2017 Mitsubishi Tanabe Pharma Corporation and Daiichi Sankyo Company enter into a marketing alliance agreement for canagliflozin/teneligliptin for Type 2 diabetes mellitus
  • 15 Dec 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top